^
Association details:
| Biomarker: | CD38 positive |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | SAR442257 (CD3 agonist, CD38 inhibitor, CD28 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CART-CELL ACTIVITY AGAINST LARGE B-CELL LYMPHOMA
Published date:
05/11/2023
Excerpt:
Cytotoxicity assays showed that SAR442257significantly increased the killing of CAR T-cells against HT and RL WT (CD19+/CD38+) cells (24-hr HT P-value=3e-4, 24-hr RL P-value=1e-2) which persisted at 48 hours...The CD38/CD28xCD3 trispecific antibody SAR442257 boosted CAR T-cell activity through recognition of CD38 on the tumor, costimulation of CAR T-cells, and induced fratricide of CD38+T-cells; resulting in superior tumor cell killing.
